Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.

ABSTRACT:

Background

Older age and comorbidities are the main risk factors for adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation.

Aims

To assess risk factors for adverse outcomes of COVID-19 in IBD patients and use the identified risk factors to build risk indices.

Methods

Observational cohort study. Univariable and multivariable logistic regression was used to identify risk factors associated with pneumonia, hospitalisation, need for ventilatory support, and death.

Results

Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) had asymptomatic SARS-CoV-2 infection, 664 (70.8%) had a favourable course, and 135 (15.5%) had moderate or severe COVID-19. In UC patient

SUBMITTER: Bezzio C 

PROVIDER: S-EPMC8653024 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature